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INTRADERMAL RECOMBINANT HEPATITIS B VACCINE FOR
HEALTHCARE WORKERS WHO FAIL TO RESPOND TO
INTRAMUSCULAR VACCINE
E. Geoffrey Playford, MBBS; Patrick G. Hogan, PhD; Amolak S. Bansal, DM; Kareena Harrison, BN; David Drummond, MBBS;
David F. M. Looke, MBBS; Michael Whitby, MBBS
OBJECTIVE: To study the humoral immune responses,
safety, and tolerability of intradermal recombinant hepatitis B vac-
cination in healthcare workers (HCWs) nonresponsive to previous
repeated intramuscular vaccination.
DESIGN: An open, prospective, before–after trial.
SETTING: A tertiary referral hospital and surrounding dis-
trict health service in Queensland, Australia.
PARTICIPANTS: Hospital and community HCWs nonre-
sponsive to previous intramuscular hepatitis B vaccination.
METHODS: Intradermal recombinant hepatitis B vaccine
was administered every second week for a maximum of 4 doses.
Hepatitis B surface antibody (anti-HBs) responses were assessed
2 weeks after each dose.
RESULTS: Protective anti-HBs levels developed in 17
(94%) of 18 study subjects. Three doses resulted in seroconversion
of all responding subjects and the highest geometric mean anti-
body concentration. The vaccine was well tolerated.
CONCLUSION: More than 90% of previously nonrespon-
sive HCWs responded to intradermal recombinant hepatitis B vac-
cine with protective anti-HBs levels (Infect Control Hosp Epidemiol
2002;23:87-90).
Vaccination is recommended for all healthcare work-
ers (HCWs) at risk of exposure to blood and body fluids to
prevent occupational acquisition of hepatitis B virus
(HBV).1,2 However, approximately 12% of HCWs who
receive primary intramuscular vaccination fail to develop
protective hepatitis B surface antibody (anti-HBs) concen-
trations ( 10 mIU/mL)3,4 and remain at risk of occupa-
tionally acquired HBV infection.5 Risk factors for vaccine
nonresponse include male gender, older age, cigarette
smoking,3,4 renal failure,6 intragluteal vaccine administra-
tion,7 and certain HLA haplotypes.8
The optimal management of HCWs who fail to
respond to primary intramuscular vaccination is unclear.
Current guidelines1,2 recommend additional intramuscular
doses, although response rates are generally less than
50%.8-10 In contrast, response rates of approximately 90%
have been reported with intradermal hepatitis B vaccine
using either recombinant11,12 or plasma-derived vaccine.13
This study was undertaken to further assess the
humoral immune responses, safety, and tolerability of
intradermal recombinant hepatitis B vaccination in HCWs
nonresponsive to repeated previous intramuscular vacci-
nation. 
METHODS
Inclusion criteria for this study were HCWs who
had (1) previously received a primary 3-dose series and at
least 2 subsequent booster doses of hepatitis B vaccine;
(2) failed to respond to both primary and booster doses as
documented by appropriately timed postvaccination serol-
ogy; (3) received all vaccine doses intramuscularly into
the deltoid muscle; (4) not received a vaccine dose within
the previous 3 months; (5) negative baseline anti-HBs,
hepatitis B core antibody (anti-HBc), and hepatitis B sur-
face antigen (HBsAg) assays; (6) no history or laboratory
evidence of immunodeficiency or renal dysfunction; and
(7) no history of significant adverse reactions to recombi-
nant hepatitis B vaccine. The Ethics Committee of the
Princess Alexandra Hospital approved the study and all
subjects provided written informed consent.
Subjects were vaccinated with 5 µg (0.25 mL) 
of recombinant hepatitis B vaccine (Engerix B,
SmithKlineBeecham Pharmaceuticals, Philadelphia, PA)
intradermally with a 1-mL insulin syringe and a 29-gauge
needle to different sites on the volar aspect of the forearm.
A total of 4 doses was given every second week unless a
significant local or systemic reaction occurred. The vaccine
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doses were administered by 1 of 2 investigators (EGP or
KH). Direct questioning of subjects and inspection of the
injection site 48 to 72 hours after each dose detected local
reactions and other side effects such as fever.
Concentrations of anti-HBs were determined at base-
line and 2 weeks after each dose; specimens from each
patient were assayed in parallel (Enzygnost Anti-Hbs
micro, Dade Behring Diagnostics, Liederbach, Germany).
Levels of 1,000 mIU/mL or greater were not further quan-
titated; these were treated as equal to 1,000 IU/L for calcu-
lations of mean antibody concentrations. 
A protective humoral response was defined as anti-
HBs concentrations of 10 mIU/mL or greater. An anamnes-
tic-type antibody response (defined as an anti-HBs concen-
tration of 1,000 mIU/mL or greater that occurred within 2
weeks of the initial intradermal vaccine dose) was consid-
ered evidence of preexisting cellular immunity.
Log-transformed antibody concentrations (geomet-
ric mean antibody concentrations [GMCs]) were used in
summary statistics. The Fisher exact test and the
Mann–Whitney U test were used to compare proportions
and continuous variables, respectively (Minitab release 12,
Minitab Inc., State College, PA).
RESULTS
Eighteen HCWs (7 men and 11 women) were
recruited (Table 1). The median age was 42 (range, 25 to
61) years. Five subjects had a body mass index greater than
30 kg/m2 and the overall median body mass index was 25.6
(range, 20.2 to 37.3) kg/m2. Four were current cigarette
smokers. Subjects had previously received between 5 and
10 (mean, 6.3) intramuscular doses of hepatitis B vaccine,
most recently between 2 and 8 (mean, 4.6) years earlier.
HLA-DR3 and HLA-DR7, both associated with nonresponse
to hepatitis B vaccine,8 were more common among our sub-
jects than among the Australian population (28% [5 of 18] vs
10%, P > .05 and 44% [8 of 18] vs 7%, P < .001, respectively).14
Sixteen subjects received 4 intradermal doses. One
subject declined the final 2 doses following the develop-
ment of a 30-mm papular skin reaction at the vaccination
site, and another, although not experiencing any adverse
reactions, declined the fourth dose; both had anti-HBs con-
centrations of 1,000 mIU/mL or greater. One subject self-
administered the final 3 doses after demonstration of the
technique.
In response to intradermal vaccination, 17 (94%) of 18
subjects had protective anti-HBs levels: 9 (50%) had anti-
body concentrations of 1,000 mIU/mL or greater; 5 (28%),
100 to 999 mIU/mL; and 3 (17%), 10 to 99 mIU/mL (Table
1). Overall, the GMC of the subjects’ maximum response
was 291 mIU/mL (median, 804 mIU/L; interquartile range,
110 to 1,000 mIU/mL). 
Six subjects had concentrations of 1,000 mIU/mL or
greater within 2 weeks of the initial intradermal vaccine
TABLE 1
CHARACTERISTICS OF THE STUDY SUBJECTS AND MAXIMUM HEPATITIS B SURFACE ANTIBODY CONCENTRATIONS IN RESPONSE TO
INTRADERMAL VACCINATION
Maximum Time to
No. of Prior Time Since anti-HBs‡ Maximum 
Subject Gender Age (y) BMI (kg/m2) Boosters* Last Dose† (y) (mIU/mL) anti-HBs§ (wk)
1 F 28 34.3 3 3  1,000 2
2 F 41 31.2 2 8  1,000 2
3 F 61 25.7 4 9  1,000 2
4 F 40 30.1 4 4  1,000 2
5 F 47 37.3 3 5  1,000 2
6 F 37 22.9 4 3  1,000 2
7 M 25 24.3 3 2  1,000 4
8 M 38 18.3 6 5  1,000 5
9 F 46 28.8 2 2  1,000 7
10 F 28 20.2 2 2 650 7
11 M 43 26.2 7 4 340 8
12 M 44 22.1 2 3 310 6
13 F 47 30.8 2 2 260 7
14 M 29 26.1 3 8 110 10
15 F 51 22.8 3 7 90 8
16 F 26 22.4 3 6 55 7
17 M 49 25.5 3 3 25 7
18 M 52 22.6 3 7 0 —
anti-HBs = hepatitis B surface antibody; BMI = body mass index.
*Number of previous booster vaccine doses, in addition to initial three-dose primary vaccination course.
†Time (years) since last booster dose of intramuscular hepatitis B vaccine.
‡Maximum anti-HBs concentration (mIU/mL) in response to intradermal vaccination.
§Time (weeks) from first intradermal vaccine dose to development of maximum anti-HBs concentration. 
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dose, which suggested preexisting cellular immunity. The
GMC and the number of subjects responding with moder-
ate or high antibody concentrations ( 100 mIU/mL) were
highest after the third dose; no additional increase followed
the fourth dose (Table 2). 
Although women had higher GMCs (525 mIU/mL;
median, 1,000 mIU/mL; interquartile range, 260 to 1,000
mIU/mL) than did men (116 mIU/mL; median, 310
mIU/mL; interquartile range, 25 to 1,000 mIU/mL), these
responses were not significantly different (P > .1).
Similarly, the proportions of women (7 of 11) and men (2 of
7) who responded with levels of 1,000 mIU/mL or greater
did not significantly differ (P > .1). Age, body mass index,
cigarette smoking, number of previous vaccine doses, time
since last vaccine dose, and HLA type were also not signif-
icantly associated with antibody response (P > .05 for all
comparisons).
Intradermal vaccination was generally well tolerated.
One high-antibody responder had a 30-mm erythematous
papule following the second vaccine dose, which persisted
for 1 week, and another had a 20-mm reaction after the
fourth dose. All other responding subjects had skin reac-
tions at the vaccine site, but these were 10 mm or less in
diameter. The sole nonresponding subject failed to have
such a skin reaction. Faint pigmentation at injection sites
occurred commonly and persisted for at least 3 months. No
other adverse reactions (eg, fever) were noted.
DISCUSSION
In this study, 17 of 18 HCWs had protective anti-
HBs levels following intradermal vaccination. These
HCWs were previously considered unlikely ever to
respond to hepatitis B vaccination, all having failed to
seroconvert despite repeated previous intramuscular vac-
cine doses and most having risk factors associated with
nonresponse.
Primary intradermal hepatitis B vaccination has
been associated with poorer seroconversion rates and
lower anti-HBs levels than intramuscular vaccination,15 pos-
sibly reflecting lower vaccine doses, inadvertent subcuta-
neous vaccine administration, or both. Similar to others,11
in this study we sought to optimize vaccine responsiveness
by using higher vaccine doses and personnel experienced
in administering intradermal injections. The antibody
responses elicited by intradermal vaccination in this study
were relatively high: half of the subjects had a maximum
anti-HBs concentration of 1,000 mIU/mL or greater and an
additional 28% had a maximum anti-HBs concentration of
100 to 999 mIU/mL. These concentrations are higher than
those of other studies of intradermal vaccination of HCWs
nonresponsive to intramuscular vaccination.11-13
Six subjects had anti-HBs concentrations of 1,000
mIU/mL or greater within 2 weeks of the initial intrader-
mal vaccine dose, which suggests the presence of preexist-
ing HBsAg-specific cellular immunity. However, because all 
subjects had well-documented negative anti-HBs levels fol-
lowing previous repeated intramuscular vaccine doses, as
well as at baseline prior to intradermal vaccination, it
appears unlikely that protective antibody responses had
previously developed. Negative baseline anti-HBc serology
in all subjects makes the possibility of previous natural
HBV infection unlikely. However, it does remain possible
that cellular immunity was induced by previous intramus-
cular vaccination, but that humoral responses were either
absent or of such a transient or low-level nature that they
escaped detection. Although protection from occupational-
ly acquired HBV infection may be conferred in such situa-
tions, knowledge of previous anti-HBs seroconversion is
the critical determinant for postexposure management
decisions.1,2 Thus, induction of protective antibody levels
remains the important endpoint.
The duration of protection from HBV infection con-
ferred by intradermal vaccination is uncertain. It is cur-
rently believed that prolonged protection from clinically
significant infection, independent of subsequent waning
antibody concentrations, is conferred to individuals who
have an initial protective response to intramuscular vacci-
nation.16 We would expect that HCWs who respond to intra-
dermal vaccination should also experience prolonged pro-
tection,16,17 despite the lower peak antibody responses
elicited by intradermal vaccination.18
The mechanism by which intradermal vaccination,
but not repeated previous intramuscular vaccination, elicit-
ed protective antibody responses in our subjects is uncer-
TABLE 2
HEPATITIS B SURFACE ANTIBODY CONCENTRATIONS IN STUDY SUBJECTS FOLLOWING INTRADERMAL VACCINATION
Anti-HBs
Concentration No. (%) of Subjects With anti-HBs Concentration at Each Time Point
(mIU/mL) Before ID Vaccination After 1 Dose After 2 Doses After 3 Doses After 4 Doses
< 10 18 (100) 5 (36) 3 (19) 1 (6) 1 (6)
10–99 0 0 4 (25) 3 (18) 4 (25)
100–999 0 3 (21) 2 (13) 5 (29) 7 (44)
 1,000 0 6 (43) 7 (44) 8 (47) 4 (25)
GMC (mIU/mL) 0 65 108 283 247
anti-HBs = hepatitis B surface antibody; GMC = geometric mean antibody concentration; ID = intradermal.
Note: After the first and second ID vaccine doses, 4 and 2 subjects, respectively, did not have anti-HBs concentrations assessed. One subject who did not receive the third and fourth vaccine doses
had already responded with an anti-HBs concentration of 1,000 mIU/mL or greater. Another subject who did not receive the fourth dose also had responded with a concentration of 1,000 mIU/mL or
greater.
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tain. Interactions among antigen-presenting cells, T lym-
phocytes, and antigens may be more effective following
intradermal vaccination. This may result from a greater
concentration of these cells, more efficient antigen presen-
tation, or more prolonged vaccine persistence occurring
within the dermis.19-21 Intradermal vaccination has also
been successful in nonresponsive patients with chronic
renal failure.22
On the basis of our results, we recommend that non-
responsive HCWs receive three intradermal vaccine doses
followed by assessment of anti-HBs. For persistent nonre-
sponders, it is unclear whether additional doses would
induce seroconversion.
We have demonstrated that intradermal recombinant
hepatitis B vaccination induced protective antibody
responses in more than 90% of HCWs nonresponsive to
intramuscular hepatitis B vaccination. It was safe and well
tolerated, and thus should be considered for all nonrespon-
sive HCWs. 
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